Orphazyme seeks shareholder support in future capital raise
Biotech firm Orphazyme has called an extraordinary general meeting hoping that shareholders will authorize new share issuances.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
If Orphazyme is to realize its dream of sending drug candidate arimoclomol to market, the biotech company needs more money.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme upgrades after careful spending year
For subscribers
Orphazyme makes changes to board of directors
For subscribers
Orphazyme to discuss NPC rejection with FDA in mid-October
For subscribers
